Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Return to Table of Contents

Table 2b. Recommendations for coadministering antiretroviral drugs with rifampin in children – 2013

Antiretroviral drug regimen choices*

Recommended change in dose of antiretroviral drug

Recommended change in dose of rifampin

Comments

“Super-boosted” lopinavir / ritonavir
+ 2 NRTIs

Pediatric weight-adjusted dosing for lopinavir/ritonavir* (Kaletra™)PLUSadded ritonavir to reach mg to mg parity of lopinavir and ritonavir doses

No change

Preferred.

Zidovudine/lamivudine/abacavir

None
(standard pediatric weight-adjusted dosing*)

No change

Alternative for children <3 years

Efavirenz + 2 NRTIs

None
(standard pediatric weight-adjusted dosing*)

No change

Efavirenz AUC ↓ by 20-30% on average, though effect is highly variable.

Alternative for children age >3 years.

Careful monitoring of virologic response; therapeutic drug monitoring of efavirenz levels if available

* For pediatric dosing see: Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011; pp 1-268. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.

 
  • Page last reviewed: September 24, 2012
  • Page last updated: December 9, 2013
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO